Hyperuricemia as a risk factor for cardiovascular disease

Expert Review of Cardiovascular Therapy

Volumn 13, Issue 1, 2015, Pages 19-20

  Katsiki, Niki ^a   Doumas, Michael ^a,b   Athyros, Vasilios G ^a   Karagiannis, Asterios ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b GEORGE WASHINGTON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIDIABETIC AGENT; ANTILIPEMIC AGENT; ATORVASTATIN; CALCIUM CHANNEL BLOCKING AGENT; DAPAGLIFLOZIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LOSARTAN; THIAZIDE DIURETIC AGENT; URIC ACID;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CHRONIC KIDNEY DISEASE; DIABETES MELLITUS; DYSLIPIDEMIA; HUMAN; HYPERTENSION; HYPERURICEMIA; ISCHEMIC HEART DISEASE; KIDNEY FUNCTION; LETTER; METABOLIC SYNDROME X; MORTALITY; NONALCOHOLIC FATTY LIVER; OBESITY; RISK REDUCTION; URIC ACID BLOOD LEVEL; WEIGHT REDUCTION; BLOOD; CARDIOVASCULAR DISEASES; COMPLICATION;

CARDIOVASCULAR DISEASES; HUMANS; HYPERURICEMIA; URIC ACID;

EID: 84919460605     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/14779072.2015.987129     Document Type: Letter

References (11)

1. Borghi C, Verardi FM, Pareo I, et al. Hyperuricemia andcardiovascular disease risk. Expert Rev Cardiovasc Ther 2014; 12(10):1219-25
2. Katsiki N, Karagiannis A, Athyros VG, Mikhailidis DP. Hyperuricaemia: morethan just a cause of gout J Cardiovasc Med (Hagerstown) 2013;14:397-402
3. Thomas MC. Renal effects of dapagliflozin in patients with type 2 diabetes. Ther Adv Endocrinol Metab 2014;5:53-61
4. Athyros VG, Hatzitolios AI, Karagiannis A, et al. improving the implementation of current guidelines for the management of major coronary heart disease risk factors by multifactorial intervention. The IMPERATIVE renal analysis. Arch Med Sci 2011;7:984-92
5. Athyros VG, Karagiannis A, Ganotakis ES, et al. Association between the changes in renal function and serum uric acid levels during multifactorial intervention and clinical outcome in patients with metabolic syndrome. A post hoc analysis of the ATTEMPT study. Curr Med Res Opin 2011;27:1659-68
6. Høieggen A, Alderman MH, Kjeldsen SE, et al. The impact of serum uric acid on cardiovascular outcomes in the LIFE study. Kidney Int 2004;65:1041-9
7. Athyros VG, Elisaf M, Papageorgiou AA, et al. GREACE Study Collaborative Group: effect of statins versus untreated dyslipidemia on serum uric acid levels in patients with coronary heart disease. A subgroup analysis of the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study. Am J Kidney Dis 2004;43:589-99
8. Katsiki N, Papanas N, Fonseca VA, et al. Uric acid and diabetes: is there a link Curr Pharm Des 2013;19:4930-7
9. Katsiki N, Athyros VG, Karagiannis A, Mikhailidis DP. Hyperuricaemia andnon-alcoholic fatty liver disease (NAFLD): a relationship with implications for vascular risk Curr Vasc Pharmacol 2011;9:698-705
10. Richette P, Perez-Ruiz F, Doherty M, et al. Improving cardiovascular and renal outcomes in gout: what should we target Nat Rev Rheumatol 2014;10(11):654-61
11. Karagiannis A, Mikhailidis DP, Tziomalos K, et al. Serum uric acid as an independent predictor of early death after acute stroke. Circ J 2007;71:1120-7